Cerenome Inc (CNSY) Q3 2026 Earnings Call Highlights: CNSide Diagnostic Revenue Debuts at $0. ...
Cerenome Inc (CNSY) posted a wider $8.7 million net loss but touted rapid CNSide commercialization, a $10-$12.5 million gross billings exit run rate, and encouraging multi-dose REYOBIQ data ahead of Related Stocks: CNSY ,